Protein kinase C beta type (PKCβ)

Protein kinase C beta (PKCβ) is a serine/threonine kinase belonging to the conventional PKC subfamily, requiring calcium and diacylglycerol for activation [1, 5]. It is encoded by the PRKCB gene and exists as two splice variants, PKCβ1 and PKCβ2, which differ in their C-terminal sequences [7, 9]. The PKCβ2 isoform is particularly significant in mediating cellular responses to hyperglycemia and is a key driver of vascular dysfunction [2, 13]. Biologically, PKCβ is essential for B-cell receptor signaling, platelet activation, and the regulation of endothelial permeability [11, 12]. In disease, its dysregulation is a hallmark of diabetic complications, including retinopathy and nephropathy, where it promotes oxidative stress and inflammation [4, 13]. It also plays a prominent role in oncology, specifically in the survival and proliferation of B-cell malignancies and certain solid tumors [6, 15]. Pharmacological intervention has focused on selective inhibitors like ruboxistaurin for diabetic microangiopathy and enzastaurin for cancer [7, 10]. These drugs typically act through ATP-competitive inhibition to prevent the phosphorylation of downstream effectors like NF-κB [14, 16]. Clinical challenges include achieving high isoform selectivity to avoid off-target effects and managing side effects such as gastrointestinal distress [10, 16].

Other names

PKC-betaPRKCBPRKCB1PRKCB2Protein kinase C betaPKC-B

ATP-competitive inhibition of Protein kinase C beta kinase activity